Showing results (51-60 of 172) with videos related to

Sort By:
Pageof 18
The Journal of Urology|November 13, 2004
Association of the cyclin D1 gene G870A polymorphism with susceptibility to sporadic renal cell carcinomaJiangang Yu, Tomonori Habuchi, Norihiko Tsuchiya, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 8, 2013
Deletion of Crry and DAF on murine platelets stimulates thrombopoiesis and increases factor H-dependent resistance of peripheral platelets to complement attackLidia Barata, Takashi Miwa, Sayaka Sato, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 29, 2023
MASP3 Deficiency in Mice Reduces but Does Not Abrogate Alternative Pathway Complement Activity Due to Intrinsic Profactor D ActivityDamodar Gullipalli, Takashi Miwa, Madhu Golla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinomaYohei Horikawa, Christopher G Wood, Hushan Yang, et al.
Clinical Practice and Epidemiology in Mental Health : CP & EMH|March 7, 2014
The effects of the combination of cognitive training and supported employment on improving clinical and working outcomes for people with schizophrenia in JapanSayaka Sato, Kazuhiko Iwata, Shun-Ichi Furukawa, et al.
International Journal of Clinical Oncology|April 20, 2007
Lymphatic invasion is a prognostic factor for bladder cancer treated with radical cystectomyYohei Horikawa, Teruaki Kumazawa, Shintaro Narita, et al.
Oncology Reports|June 26, 2008
Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladderYohei Horikawa, Junichi Nadaoka, Mitsuru Saito, et al.
Biochemical and Biophysical Research Communications|May 11, 2005
An A/G polymorphism of core 2 branching enzyme gene is associated with prostate cancerLizhong Wang, Junya Mitoma, Norihiko Tsuchiya, et al.
Hinyokika Kiyo. Acta Urologica Japonica|April 28, 2005
[Active combination immunochemotherapy with interferon-alpha, interleukin-2 and gemcitabine for four patients with metastatic renal cell carcinoma]Takamitsu Inoue, Chikara Ohyama, Shingo Hatakeyama, et al.
Pageof 18